ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1700

Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients

Cristina Reategui-Sokolova1, Rocío Gamboa-Cárdenas1, Mariela Medina-Chinchon1, Francisco Zevallos1, Claudia Elera-Fitzcarrald1,2, Victor R. Pimentel-Quiroz1, Mariano Cucho-Venegas1, Zoila Rodriguez-Bellido1, Cesar A. Pastor-Asurza1,3, Risto Perich-Campos1, Graciela S. Alarcón4,5 and Manuel Ugarte-Gil6,7, 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Universidad Científica del Sur, Lima, Peru, 3Universidad Nacional Mayor de San Marcos, Lima, Peru, 4Universidad Peruana Cayetano Heredia, Lima, Peru, 5Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Rheumatology, Universidad Científica del Sur, Lima, Peru, 7Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: remission and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Although the survival rate of patients with Systemic Lupus Erythematosus (SLE) has improved over the years, patients are frequently hospitalized or evaluated in the Emergency Room; these events account for most of the direct cost of these patients’ care. The objective of this study was to determine whether remission and low disease activity state (LDAS) are protective of hospitalizations and Emergency Room visits in our SLE patients.

Methods:

All hospitalizations and Emergency Room visits of Peruvian SLE patients members of a single center cohort were identified during the two-years following their baseline visit. We used the baseline data (at cohort entry) to determine which factors were associated with hospitalizations and Emergency Room visits in these patients. Remission was defined as a SLEDAI-2K=0, prednisone ≤5mg/d and immunosuppressants on maintenance dose, LDAS was defined as not on remission an a SLEDAI-2K≤4, prednisone ≤7.5mg/d and immunosuppressants on maintenance dose; antimalarials were allowed in both groups(1). Univariable and multivariable Poisson regression models were used to determine the impact of being on remission or LDAS on the risk of hospitalization and Emergency Room visits, adjusting for gender, age at diagnosis, socioeconomic status, disease duration, damage, comorbidities, time of exposure to prednisone and antimalarial use.

Results:

Of the 314 cohort patients, 92.7% (n = 291) were female, the median age of the patients was 40.7 (32.9-51.1) years, with a disease duration of 5.5 (2.6-10.3) years. Fifty-nine of the patients included were hospitalized, a total of 165 times (range 2.8 per patient). In the multivariable analysis we found that remission [RR 0.036 (0.005-0.259), p=0.001] and LDAS [RR 0.289 (0.182-0.457), <p=0.001] at baseline decrease the risk of hospitalization in SLE patients. Similarly, remission [RR: 0.019 (CI95%: 0.107-0.815), p=0.019] and LDAS [RR=0.383 (CI95%: 0.222-0.661), p=0.001] decrease the risk of Emergency Room visits. One hundred- thirty-five of the 165 hospitalizations presented a defined cause, being disease activity the most common cause of hospitalization with 73 admissions (54.1%); within them, renal disease was the leading cause, with 37 admissions (50.7%).

Conclusion:

Remission and LDAS decrease the risk of hospitalizations and Emergency Room visits in SLE patients. Disease activity was the most frequent cause of hospitalization and within them, renal disease. These findings have economic implications for the health care system.

Reference:

  1. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, et al. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis.2017 Dec;76(12):2071-2074

Disclosure: C. Reategui-Sokolova, None; R. Gamboa-Cárdenas, None; M. Medina-Chinchon, None; F. Zevallos, None; C. Elera-Fitzcarrald, None; V. R. Pimentel-Quiroz, None; M. Cucho-Venegas, None; Z. Rodriguez-Bellido, None; C. A. Pastor-Asurza, None; R. Perich-Campos, None; G. S. Alarcón, None; M. Ugarte-Gil, None.

To cite this abstract in AMA style:

Reategui-Sokolova C, Gamboa-Cárdenas R, Medina-Chinchon M, Zevallos F, Elera-Fitzcarrald C, Pimentel-Quiroz VR, Cucho-Venegas M, Rodriguez-Bellido Z, Pastor-Asurza CA, Perich-Campos R, Alarcón GS, Ugarte-Gil M. Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/remission-and-low-disease-activity-state-prevent-hospitalizations-and-emergency-room-visits-in-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/remission-and-low-disease-activity-state-prevent-hospitalizations-and-emergency-room-visits-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology